MAPK3 and cardiac hypertrophy: In addition to confirming the role of CTGF during cardiac hypertrophy and possible therapeutic targets, this study also revealed a coordinated regulation model based on ERK1/2, suggesting that ERK1/2 signaling pathway may be an important control link for mitigation of cardiac hypertrophy treatment.